Genevant Sciences Ltd., a new Cambridge, Mass.-based venture with $37.5 million in committed seed funding from Roivant Sciences Ltd., is aiming to get five to 10 RNA-based therapies into the clinic by 2020 using technology from Vancouver, British Columbia-based Arbutus Biopharma Corp. The jointly owned company will develop RNAi, mRNA and gene editing candidates in-house, a departure from Roivant's typical in-licensing strategy. Genevant will focus on a wide range of genetic diseases, both orphan and non-orphan, Roivant spokesman Paul Davis told BioWorld.